STOCK TITAN
  1. Home
  2. Sec-filings
  3. QTRX
  4. [8-K] Quanterix Corp Reports Material Event

Jason Faessler joins Quanterix (QTRX) as Chief Financial Officer and Treasurer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Quanterix Corporation has appointed Jason Faessler as its new Chief Financial Officer and Treasurer, with employment expected to begin on June 22, 2026. He brings senior finance leadership experience from Bruker Corporation, PAREXEL, EMC and Harvard Business Publishing, with a background in strategic planning and operational finance.

Under an employment agreement dated May 31, 2026, Faessler will receive an initial annual base salary of $475,000, a $200,000 cash sign-on bonus, and is eligible for an annual performance bonus targeted at up to 50% of base salary. He will also receive restricted stock units equal to 0.30% of Quanterix’s outstanding common shares on his start date, vesting in four equal annual installments.

If his employment is terminated without Cause or he resigns for Good Reason, Faessler is entitled to 12 months of base salary continuation, a pro-rated target bonus, and subsidized health benefits. If such a termination occurs in connection with a Change-in-Control, he also receives full vesting of outstanding unvested equity awards.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
CFO base salary $475,000 per year Initial annualized base salary under employment agreement dated May 31, 2026
Sign-on bonus $200,000 Cash sign-on bonus for Jason Faessler upon joining as CFO
Bonus target 50% of base salary Annual performance bonus target for new CFO
Equity award size 0.30% of shares RSUs equal to 0.30% of Quanterix common stock outstanding on start date
RSU vesting term 4 years RSUs vest in four equal annual installments from start date
Severance period 12 months Base salary continuation if terminated without Cause or for Good Reason
restricted stock units (RSUs) financial
"a long-term equity incentive award consisting of restricted stock units (RSUs) covering shares of the Company’s common stock"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Good Reason financial
"he resigns for Good Reason (as defined in the Employment Agreement), then he will receive continued payment of his base salary"
Cause financial
"terminated by the Company without Cause (as defined in the Employment Agreement) or he resigns for Good Reason"
Change-in-Control financial
"terminated by the Company without Cause or he resigns for Good Reason in connection with a Change-in-Control (as defined in the Employment Agreement)"
A change-in-control is a transaction or event that shifts who ultimately owns or runs a company—such as a sale, merger, or transfer of a majority of voting shares—and often triggers contractual protections, payoffs or rule changes. Investors care because it can instantly alter a company’s leadership, strategy, cash flows and the value or timing of stock payouts, much like handing a house’s keys to a new owner who may change the rules and distribute proceeds differently.
Regulation FD regulatory
"Item 7.01 Regulation FD Disclosure. On June 9, 2026, the Company issued a press release"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
Item 404(a) of Regulation S-K regulatory
"no transactions to which the Company is a party and in which Mr. Faessler has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false000150327400015032742026-06-092026-06-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________
FORM 8-K
______________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 9, 2026
_________________________________________________
QUANTERIX CORPORATION
(Exact name of registrant as specified in its charter)
_________________________________________________
Delaware001-3831920-8957988
(State or other jurisdiction
of incorporation)		(Commission File Number)(IRS Employer
Identification No.)
900 Middlesex Turnpike
Billerica, MA
01821
(Address of principal executive offices)
(Zip Code)
(617) 301-9400
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading symbol(s):
Name of each exchange on which
registered:
Common Stock, $0.001 par value per shareQTRXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The Board of Directors of Quanterix Corporation (the “Company”) has appointed Jason Faessler as the Chief Financial Officer and Treasurer of the Company. He is expected to commence employment with the Company on June 22, 2026.
Mr. Faessler mostly recently was employed by Brucker Corporation as Senior Vice President of Finance, leading global FP&A and the Americas finance organization. His responsibilities have included strategic planning, operational finance and capital decision-making. Before that, he was Senior Director of Finance at Parexel Corporation from April 2018 to December 2018 and Director of Finance at Parexel from November 2015 to April 2018, where he led its early- and late-phase clinical divisions, driving growth and profitability across both businesses. Prior to Parexel, Mr. Faessler worked as Director of Finance and Sales Operations at Harvard Business Publishing and held several financial planning, analysis and operation roles at EMC Corporation. Mr. Faessler earned an MBA from the F.W. Olin Graduate School of Business at Babson College and a BA from the University of Massachusetts Boston.
The Company has entered into an employment agreement dated May 31, 2026 with Mr. Faessler (the “Employment Agreement”) in connection with his appointment as Chief Financial Officer and Treasurer. The Employment Agreement provides for an initial annualized base salary of $475,000, a cash sign-on bonus of $200,000, and eligibility for an annual performance bonus with an annual bonus target of up to 50% of Mr. Faessler’s base salary.
In connection with his appointment, Mr. Faessler also will receive a long-term equity incentive award consisting of restricted stock units (RSUs) covering shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), equivalent to three-tenths of one percent (0.30%) of the shares of Common Stock outstanding on his start date. The RSUs vest in four equal annual installments on each of the first four anniversaries of Mr. Faessler’s start date.
If Mr. Faessler’s employment is terminated by the Company without Cause (as defined in the Employment Agreement) or he resigns for Good Reason (as defined in the Employment Agreement), then he will receive continued payment of his base salary for 12 months (the “Severance Period”), payment of an amount equal to his annual target bonus for the year of termination, pro-rated as of the date of termination, and subsidized health benefits during the Severance Period. If Mr. Faessler’s employment is terminated by the Company without Cause or he resigns for Good Reason in connection with a Change-in-Control (as defined in the Employment Agreement), then he will receive continued payment of his base salary for 12 months, payment of an amount equal to his annual target bonus for the year of termination, subsidized health benefits during the Severance Period, and all of his outstanding but unvested equity awards will also become fully vested. Receipt of the foregoing termination benefits will be subject to Mr. Faessler’s execution of a separation agreement, including certain restrictive covenants and a general release of all claims, in a form acceptable to the Company.
A copy of the Employment Agreement is filed as Exhibit 10.1 and is incorporated herein by reference.
Except for the Employment Agreement, there are no arrangements or understandings between Mr. Faessler and any other person pursuant to which Mr. Faessler was appointed as an officer. There are no family relationships between Mr. Faessler and any director, director nominee or executive officer of the Company. There are no transactions to which the Company is a party and in which Mr. Faessler has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K.
Item 7.01    Regulation FD Disclosure.
On June 9, 2026, the Company issued a press release, which announced the appointment of Mr. Faessler as Chief Financial Officer and Treasurer of the Company (the “Release”). A copy of the Release is attached as Exhibit 99.1 and incorporated herein by reference.
The information contained or incorporated in this Item 7.01, including Exhibit 99.1, is being furnished, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01    Financial Statements and Exhibits.
(d)Exhibits
Exhibit
No.		Description
10.1
Employment Agreement by and between the Company and Jason Faessler
99.1
Press Release dated June 9, 2026
104Cover Page Interactive Data File (embedded within the inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: June 9, 2026
QUANTERIX CORPORATION
By:/s/ Daniel S. Char
Name:
Daniel S. Char
Title:
Chief Legal Officer and Corporate Secretary

Exhibit 99.1
Quanterix Announces Appointment of Jason Faessler
as Chief Financial Officer

BILLERICA, Mass.—June 9, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company’s new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry, positioning him to play a pivotal role in executing Quanterix’s strategic growth plans in the coming years.
“We are thrilled to welcome Jason to the Quanterix leadership team,” said Everett Cunningham, Chief Executive Officer of Quanterix. “His extensive track record within life science organizations makes him the ideal leader to support our ambitious growth objectives. Jason’s expertise in strategic financial and capital planning, operational excellence, and commercial support will be instrumental in advancing our mission.”
Faessler joins Quanterix from Bruker Corporation, where he served as Senior Vice President, leading global FP&A and the Americas Finance organization. His responsibilities have included strategic planning, operational finance, and capital decision-making. Prior to Bruker, Faessler held senior finance leadership positions at PAREXEL, where he led its Early- and Late-Phase Clinical divisions, driving growth and profitability across both businesses. Jason also held senior financial management roles at EMC (now Dell) and Harvard Business Publishing.
“I am both excited and honored to join Quanterix at this pivotal moment in its journey,” Faessler adds. “The Company is uniquely positioned for growth with two leading scientific instrument platforms and an emerging diagnostics capability. Quanterix’s technology is enabling earlier disease detection and deeper insights into both research and clinical settings, helping to advance science and improve patient outcomes. I look forward to partnering with Everett and the leadership team to drive sustained value creation for our shareholders by capturing these opportunities.”
About Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,500 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,450 installed instruments. Together, the combined company offers a uniquely integrated platform that connects


biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.

Media
media@quanterix.com
Investor Relations
Joshua Young
ir@quanterix.com

Source: View Original Filing on SEC EDGAR

FAQ

What executive change did Quanterix (QTRX) announce in this 8-K?

Quanterix appointed Jason Faessler as Chief Financial Officer and Treasurer. He is expected to start on June 22, 2026, bringing senior finance leadership experience from Bruker, PAREXEL, EMC and Harvard Business Publishing.

What is Jason Faessler’s compensation package at Quanterix (QTRX)?

Jason Faessler will receive a $475,000 annual base salary and a $200,000 cash sign-on bonus. He is also eligible for an annual performance bonus up to 50% of base salary, plus equity awards in restricted stock units.

What equity award will Quanterix (QTRX) grant to its new CFO?

Quanterix will grant Jason Faessler restricted stock units equal to 0.30% of outstanding common shares on his start date. These RSUs vest in four equal annual installments over four years, aligning compensation with shareholder value.

What severance protections does the new Quanterix (QTRX) CFO have?

If terminated without Cause or resigning for Good Reason, Faessler receives 12 months of base salary, a pro-rated target bonus, and subsidized health benefits. In a Change-in-Control termination, all unvested equity awards also fully vest.

How did Quanterix (QTRX) publicly announce the CFO appointment?

On June 9, 2026, Quanterix issued a press release announcing Jason Faessler’s appointment as Chief Financial Officer and Treasurer. That release was furnished as Exhibit 99.1 and not deemed filed for Exchange Act Section 18 liability purposes.

Filing Exhibits & Attachments

5 documents

Press Releases

Agreements & Contracts

Other Documents